AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31283409 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant three-dimensional conformal radiotherapy (RT) followed by hepatectomy
Number of subjects: 164
Study 31283409 — intervention group
Group type: COMPARATOR
Intervention: Hepatectomy alone
Number of subjects: 164
Study 27738823 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation group (ERG)
Number of subjects: 40
Study 27738823 — intervention group
Group type: COMPARATOR
Intervention: Conventional care group (CG)
Number of subjects: 40
Study 24678649 — intervention group
Group type: EXPERIMENTAL
Intervention: Early clamping (EC, within 10 s of delivery)
Number of subjects: 229
Study 24678649 — intervention group
Group type: COMPARATOR
Intervention: Late clamping (LC, at 2 min)
Number of subjects: 229
Study 25129066 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone therapy
Number of subjects: 534
Study 25129066 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of spironolactone in patients not on it before admission
Number of subjects: 534
Study 22275397 — intervention group
Group type: EXPERIMENTAL
Intervention: Certoparin 3000 IU subcutaneously once daily for 6 months
Number of subjects: 442
Study 22275397 — intervention group
Group type: COMPARATOR
Intervention: Placebo subcutaneously once daily for 6 months
Number of subjects: 442
Study 19706577 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at a dose range of 33 to 67 microg/kg per day
Number of subjects: 391
Study 19706577 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated SGA subjects)
Number of subjects: 391
Study 17519435 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/day)
Number of subjects: 53
Study 17519435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 15448286 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention with monthly contact by case managers
Number of subjects: 352
Study 11843450 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon fiber-reinforced composite post
Number of subjects: 30
Study 11843450 — intervention group
Group type: COMPARATOR
Intervention: Prefabricated stainless steel post
Number of subjects: 30
Study 11843450 — intervention group
Group type: COMPARATOR
Intervention: Cast post-and-core
Number of subjects: 30
Study 9808101 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy group
Number of subjects: 72
Study 9808101 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 7715644 — intervention group
Group type: EXPERIMENTAL
Intervention: Special unit care designed to help older persons maintain or achieve independence in self-care activities.
Number of subjects: 651
Study 7715644 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 651
Study 7715644 — intervention group
Group type: EXPERIMENTAL
Intervention: Special unit care
Number of subjects: 651
Study 2620839 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence group
Number of subjects: 0
Study 2620839 — intervention group
Group type: EXPERIMENTAL
Intervention: Current topics discussion group
Number of subjects: 0
Study 2620839 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 989378 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (50 mg i.v.)
Number of subjects: 0
Study 989378 — intervention group
Group type: COMPARATOR
Intervention: Control (no melatonin)
Number of subjects: 0
Study 31292190 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular renal denervation (RDN) using either radiofrequency energy or ultrasound-based approaches
Number of subjects: 0
Study 31292190 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 28377392 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+TRT (Resistance Training + Testosterone Replacement Therapy)
Number of subjects: 26
Study 28377392 — intervention group
Group type: COMPARATOR
Intervention: TRT (Testosterone Replacement Therapy)
Number of subjects: 26
Study 26964170 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion (group A)
Number of subjects: 80
Study 26964170 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-sensitive acupuncture (group B)
Number of subjects: 80
Study 26964170 — intervention group
Group type: EXPERIMENTAL
Intervention: Force-sensitive acupuncture (group C)
Number of subjects: 80
Study 26964170 — intervention group
Group type: EXPERIMENTAL
Intervention: Force-sensitive moxibustion (group D)
Number of subjects: 80
Study 24257393 — intervention group
Group type: EXPERIMENTAL
Intervention: IV arginine vasopressin (AVP) 0.07 U/kg
Number of subjects: 30
Study 24257393 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 30
Study 21450542 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopist-administered propofol sedation
Number of subjects: 90
Study 21450542 — intervention group
Group type: COMPARATOR
Intervention: Anaesthetist-administered deep sedation
Number of subjects: 90
Study 19575117 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical adrenaline 1:2,000
Number of subjects: 49
Study 19575117 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical adrenaline 1:10,000
Number of subjects: 49
Study 19575117 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical adrenaline 1:50,000
Number of subjects: 49
Study 19575117 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study 17708740 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (anti-IL-6 receptor monoclonal antibody)
Number of subjects: 0
Study 15140425 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopharmaceuticals targeting specific disease‐mediating molecules
Number of subjects: 0
Study 15140425 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro and in vivo studies
Number of subjects: 0
Study 15140425 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental strategies
Number of subjects: 0
Study 11396561 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Breathing System (EBS) used by 4 to 11 subjects
Number of subjects: 132
Study 11396561 — intervention group
Group type: EXPERIMENTAL
Intervention: Buoyancy of the survival suit
Number of subjects: 132
Study 11396561 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fuselage evacuation time
Number of subjects: 132
Study 9609610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 214
Study 9609610 — intervention group
Group type: COMPARATOR
Intervention: Ebastine 10 mg
Number of subjects: 214
Study 8205804 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted least squares method
Number of subjects: 0
Study 8205804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochran‐Mantel‐Haenszel estimator
Number of subjects: 0
Study 8205804 — intervention group
Group type: COMPARATOR
Intervention: Both methods
Number of subjects: 0
Study 1700551 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous gammaglobulin administration
Number of subjects: 30
Study 1700551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 791448 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6
Study 791448 — intervention group
Group type: COMPARATOR
Intervention: D-propranolol
Number of subjects: 6
Study 791448 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing doses of propranolol
Number of subjects: 6
Study 30658933 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected samples
Number of subjects: 7643
Study 30658933 — intervention group
Group type: COMPARATOR
Intervention: Clinician-collected samples
Number of subjects: 7643
Study 28572633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive ability
Number of subjects: 112151
Study 28572633 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational attainment
Number of subjects: 112151
Study 28572633 — intervention group
Group type: COMPARATOR
Intervention: Health to cognitive ability
Number of subjects: 112151
Study 28572633 — intervention group
Group type: COMPARATOR
Intervention: Educational attainment to physical health
Number of subjects: 112151
Study 25125508 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention
Number of subjects: 211
Study 25125508 — intervention group
Group type: COMPARATOR
Intervention: Standard of healthcare (control group)
Number of subjects: 211
Study 23223507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis (treatment arm)
Number of subjects: 44
Study 23223507 — intervention group
Group type: COMPARATOR
Intervention: Control (no intra-arterial thrombolysis)
Number of subjects: 44
Study 16829095 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor (C1‐INH) administration (40 IU kg(‐1) during reperfusion and 20 IU kg(‐1) 6 h postoperatively)
Number of subjects: 67
Study 16829095 — intervention group
Group type: COMPARATOR
Intervention: CABG+STEMI (without C1‐INH)
Number of subjects: 67
Study 16829095 — intervention group
Group type: COMPARATOR
Intervention: CABG‐STEMI (control group)
Number of subjects: 67
Study 12554151 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0
Study 12554151 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10587935 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin maintenance
Number of subjects: 1146
Study 10587935 — intervention group
Group type: COMPARATOR
Intervention: Morphine maintenance
Number of subjects: 1146
Study 10587935 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance
Number of subjects: 1146
Study 8934109 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium enema examination
Number of subjects: 135
Study 1675901 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 68
Study 1675901 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 68
Study 1675901 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam
Number of subjects: 68
Study 6871085 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin
Number of subjects: 16
Study 6871085 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin
Number of subjects: 16
Study 31372864 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 91
Study 31372864 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 91
Study 31274197 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine hydrochloride 30-mg tablets
Number of subjects: 0
Study 31274197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29032916 — intervention group
Group type: COMPARATOR
Intervention: 1 mg kg−1 epidural ropivacaine
Number of subjects: 20
Study 29032916 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg kg−1 ropivacaine and 2 mg kg−1 magnesium sulphate
Number of subjects: 20
Study 25942606 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone (OXN)
Number of subjects: 453
Study 25942606 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone (OXY)
Number of subjects: 453
Study 25942606 — intervention group
Group type: COMPARATOR
Intervention: Morphine (MOR)
Number of subjects: 453
Study 25942606 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse events (TEAEs)
Number of subjects: 453
Study 23369120 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed CD-based depression training program
Number of subjects: 50
Study 23369120 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 21803869 — intervention group
Group type: EXPERIMENTAL
Intervention: RUNX1 SNPs
Number of subjects: 100
Study 21803869 — intervention group
Group type: EXPERIMENTAL
Intervention: IUS exposure
Number of subjects: 100
Study 21803869 — intervention group
Group type: EXPERIMENTAL
Intervention: Murine model with IUS
Number of subjects: 100
Study 19769482 — intervention group
Group type: EXPERIMENTAL
Intervention: GengNianLe (GNL)
Number of subjects: 47
Study 19769482 — intervention group
Group type: COMPARATOR
Intervention: Tibolone (Control)
Number of subjects: 47
Study 16702931 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cyanotic congenital heart diseases (Group 1)
Number of subjects: 20
Study 16702931 — intervention group
Group type: COMPARATOR
Intervention: Cyanotic congenital heart diseases (Group 2)
Number of subjects: 20
Study 14560344 — intervention group
Group type: COMPARATOR
Intervention: Rate control (Group I)
Number of subjects: 205
Study 14560344 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control (Group II)
Number of subjects: 205
Study 11027389 — intervention group
Group type: EXPERIMENTAL
Intervention: Trephination procedure
Number of subjects: 50
Study 11027389 — intervention group
Group type: COMPARATOR
Intervention: Mock trephination procedure (Control)
Number of subjects: 50
Study 8793433 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 300 mgI/ml
Number of subjects: 80
Study 8793433 — intervention group
Group type: COMPARATOR
Intervention: ioxaglate 320 mgI/ml
Number of subjects: 80
Study 8793433 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 80
Study 1475988 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine administered twice daily for 4 weeks
Number of subjects: 20
Study 1475988 — intervention group
Group type: COMPARATOR
Intervention: 40 mg famotidine administered once daily for 4 weeks
Number of subjects: 20
Study 1475988 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine administered twice daily for 8 weeks
Number of subjects: 20
Study 1475988 — intervention group
Group type: COMPARATOR
Intervention: 40 mg famotidine administered once daily for 8 weeks
Number of subjects: 20
Study 6486761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin aerosol treatment
Number of subjects: 0
Study 6486761 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31394228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral antegrade angioplasty
Number of subjects: 53
Study 31394228 — intervention group
Group type: COMPARATOR
Intervention: Surgical bypass
Number of subjects: 53
Study 29925341 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 57
Study 29925341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injection (IVR)
Number of subjects: 57
Study 29925341 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 57
Study 25559124 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐h MAT training plus a 12‐month linkage intervention
Number of subjects: 20
Study 25559124 — intervention group
Group type: COMPARATOR
Intervention: 3‐h training alone
Number of subjects: 20
Study 25730933 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of peloid balneotherapy with magnetic laser therapy and application of efthidermum MPE to the lumbar region
Number of subjects: 78
Study 23110376 — intervention group
Group type: EXPERIMENTAL
Intervention: 5As communication intervention (Ask, Advise, Agree, Assist, Arrange)
Number of subjects: 375
Study 23110376 — intervention group
Group type: EXPERIMENTAL
Intervention: 5As communication intervention
Number of subjects: 375
Study 20565460 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (1.5 mg transdermal patch every 72 hours for 2 weeks)
Number of subjects: 30
Study 20565460 — intervention group
Group type: COMPARATOR
Intervention: Placebo (transdermal patch every 72 hours for 2 weeks)
Number of subjects: 30
Study 20565460 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (1.5 mg transdermal patch)
Number of subjects: 30
Study 17482773 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-item Brief Questionnaire of Smoking Urges (QSU-Brief)
Number of subjects: 626
Study 17482773 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Craving Score from QSU-Brief
Number of subjects: 626
Study 17482773 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors 1 and 2 from QSU-Brief
Number of subjects: 626
Study 16264042 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 microg two inhalations b.i.d. plus additional inhalations as needed
Number of subjects: 2143
Study 16264042 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 2143
Study 16264042 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone 50/250 microg b.i.d. plus salbutamol as needed
Number of subjects: 2143
Study 11883765 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE strategy
Number of subjects: 62
Study 11883765 — intervention group
Group type: COMPARATOR
Intervention: SPEAK strategy
Number of subjects: 62
Study 11883765 — intervention group
Group type: COMPARATOR
Intervention: CIS strategy
Number of subjects: 62
Study 11883765 — intervention group
Group type: EXPERIMENTAL
Intervention: HINT sentences in quiet
Number of subjects: 62
Study 11883765 — intervention group
Group type: EXPERIMENTAL
Intervention: CUNY sentences at +10 dB signal to noise ratio
Number of subjects: 62
Study 10201415 — intervention group
Group type: EXPERIMENTAL
Intervention: Free fall startle response in young normal subjects
Number of subjects: 0
Study 10201415 — intervention group
Group type: EXPERIMENTAL
Intervention: Free fall startle response in elderly subjects
Number of subjects: 0
Study 10201415 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary tibialis EMG activation in response to startling stimulus (fall)
Number of subjects: 0
Study 10201415 — intervention group
Group type: COMPARATOR
Intervention: Free fall startle response in patients with absent vestibular function
Number of subjects: 0
Study 10201415 — intervention group
Group type: COMPARATOR
Intervention: Free fall startle response in patients with idiopathic Parkinson's disease
Number of subjects: 0
Study 10201415 — intervention group
Group type: COMPARATOR
Intervention: Free fall startle response in patients with multiple system atrophy (MSA)
Number of subjects: 0
Study 10201415 — intervention group
Group type: COMPARATOR
Intervention: Free fall startle response in patients with Steele-Richardson-Olszewski (SRO) syndrome
Number of subjects: 0
Study 7767515 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (300 micrograms)
Number of subjects: 8
Study 7767515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2152662 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, 5 mg/day
Number of subjects: 36
Study 2152662 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 36
Study 7439251 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg initially, increased to 240 or 320 mg if necessary)
Number of subjects: 34
Study 7439251 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg initially, increased to 300 or 400 mg if necessary)
Number of subjects: 34
Study 31810781 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported vaccine coverage for seasonal influenza vaccine (recommended, 2016/17 season)
Number of subjects: 1539
Study 31810781 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported vaccine coverage for Bacillus Calmette-Guérin vaccine (mandatory)
Number of subjects: 1539
Study 31810781 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine hesitancy prevalence rate
Number of subjects: 1539
Study 31810781 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine hesitancy concerning seasonal influenza or A(H1N1) vaccines
Number of subjects: 1539
Study 31810781 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine hesitancy concerning hepatitis B vaccine
Number of subjects: 1539
Study 31810781 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of VH with trust in health authorities
Number of subjects: 1539
Study 31124581 — intervention group
Group type: EXPERIMENTAL
Intervention: Medac Escherichia coli asparaginase
Number of subjects: 599
Study 31124581 — intervention group
Group type: COMPARATOR
Intervention: Erwinia asparaginase
Number of subjects: 599
Study 31124581 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (6 mg/m2/day)
Number of subjects: 599
Study 31124581 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (60 mg/m2/day)
Number of subjects: 599
Study 31124581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified CNS-directed therapy
Number of subjects: 599
Study 31124581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified induction chemotherapy
Number of subjects: 599
Study 27647659 — intervention group
Group type: EXPERIMENTAL
Intervention: DASM training with three repetitions of the anaesthesia technique (Group 1)
Number of subjects: 20
Study 27647659 — intervention group
Group type: COMPARATOR
Intervention: Control group with only theoretical lecture and clinical demonstration (Group 2)
Number of subjects: 20
Study 25464226 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with metabolic syndrome (METS)
Number of subjects: 6648
Study 25464226 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with METS and no type 2 diabetes mellitus (DM)
Number of subjects: 6648
Study 25464226 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes mellitus (DM) and no metabolic syndrome (METS)
Number of subjects: 6648
Study 25464226 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with METS and DM
Number of subjects: 6648
Study 23745533 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermosensitive poloxamer (TPX)
Number of subjects: 66
Study 23745533 — intervention group
Group type: COMPARATOR
Intervention: Merogel
Number of subjects: 66
Study 22289558 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-D (laryngeal mask airway and deep removal)
Number of subjects: 168
Study 22289558 — intervention group
Group type: COMPARATOR
Intervention: ET-A (endotracheal tube and extubation whilst awake)
Number of subjects: 168
Study 22289558 — intervention group
Group type: COMPARATOR
Intervention: ET-D (endotracheal tube and deep extubation)
Number of subjects: 168
Study 19054264 — intervention group
Group type: COMPARATOR
Intervention: Covered Niti-S stent
Number of subjects: 37
Study 19054264 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-layered Niti-S stent
Number of subjects: 37
Study 16584098 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatments
Number of subjects: 8000
Study 16584098 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care model
Number of subjects: 8000
Study 16584098 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analyses of RCTs
Number of subjects: 8000